Bufotenin
5-hydroxy-N,N-dimethyltryptamine
Viewing r1 — Apr 26, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Bufotenin (5-hydroxy-N,N-dimethyltryptamine) is a naturally-occurring psychedelic of the tryptamine class. It is a close structural relative of DMT and psilocin — but with far weaker psychedelic potency. It activates serotonin receptors but barely triggers the one responsible for classic psychedelic effects, producing a body-heavy altered state rather than vivid visuals.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
DMT, 5-MeO-DMT, psilocybin +2 moreDMT, 5-MeO-DMT, psilocybin, psilocin, LSD show less
First isolated from toad secretion in 1893 and structurally identified in 1934,[1] bufotenin is one of the oldest known psychedelic compounds. In the 1950s, researchers injected it into psychiatric patients; the results were alarming cardiovascular responses and ambiguous psychedelic effects, a debate that lasted decades.[2] It remains a Schedule I controlled substance in the United States with no approved medical use.
Subjective effects include visual distortions, euphoria, bodily heaviness, facial flushing, and brief altered states of consciousness.[3] The experience is more body-dominated than any classic psychedelic — cardiovascular pressure and physical weight come first, with genuine psychedelic content emerging only at higher doses. Tachycardia, flushing, and anxiety are consistent unsought effects across all routes.
Bufotenin produces no physical dependence, but the cardiovascular risk is real — it directly raises heart rate and the force of heart contractions.[4] The greatest additional danger comes from monoamine oxidase inhibitors, which block the enzyme that clears bufotenin and dramatically amplify cardiac exposure. Current understanding rests almost entirely on 1950s case series and animal data — no controlled human trials have been conducted.
History[edit]
Discovery
Bufotenin was first isolated from toad secretion in 1893 by Césaire Phisalix and Gabriel Bertrand.[1][2] Hans Handovsky named it "bufotenin" around 1920, after the toad genus Bufo.[2] Heinrich Wieland established its chemical structure in 1934,[1] and the first total synthesis followed in 1935.[5]
The psychoactivity debate
In 1956, Fabing and Hawkins injected bufotenin intravenous into psychiatric patients, producing alarming cardiovascular responses — flushing, racing heart, spiking blood pressure — but only weak psychedelic effects.[2] The question of whether bufotenin is genuinely hallucinogenic went unresolved for decades.[2] McBride (2000) later argued the ambiguous results reflected poor blood-brain barrier penetration, supported by animal data showing far lower brain concentrations than 5-MeO-DMT.[6][7]
Street use and scheduling
In the early 1990s, bufotenin appeared as a street drug in New York City — found in 42 seized samples, typically smoked with marijuana.[3] The United States classifies it as Schedule I (DEA Drug Code 7403),[5][8] with equivalent restrictions in the United Kingdom and Australia.
Bufotenin is a major alkaloid in Anadenanthera peregrina seeds, the primary component of traditional South American hallucinogenic snuffs known as yopo or cohoba.[3] Spanish colonizers documented cohoba use by Taíno people for ritual divination in the 15th–16th century,[3] and bufotenin has been identified in 1,200-year-old archaeological samples from northern Chile.[3]
The name derives from Bufo, the Latin genus for toads, coined by Handovsky around 1920.[2] The compound is also designated 5-HO-DMT and N,N-dimethylserotonin. Its association with toad venom has made it a subject of psychedelic folklore, though its actual psychoactive contribution to toad secretions — which also contain 5-MeO-DMT — remains debated.
Chemistry[edit]
Structural class
Bufotenin belongs to the substituted tryptamine family, sharing the indole core with DMT, psilocin, and 5-MeO-DMT.[3] Its molecular formula is C₁₂H₁₆N₂O (204.27 g/mol).
It is the N,N-dimethyl structural analog of serotonin and the 5-hydroxy positional isomer of psilocin — the two compounds differ only in where the hydroxyl group sits on the ring.[3] The N,N-dimethyl group prevents full activation of the serotonin receptor responsible for classic psychedelic effects.[9]
Pharmacology[edit]
Mechanism of action
Via most routes, bufotenin barely reaches the brain in meaningful amounts.[6] Even when it does, it activates only weakly at the main serotonin receptor linked to psychedelic effects,[5][9][10] and simultaneously activates a second serotonin receptor that suppresses any psychedelic activity that does begin.[11]
Bufotenin also directly stimulates cardiac serotonin receptors, raising heart rate and the force of contractions — confirmed in isolated human heart tissue.[4] This cardiac mechanism operates independently of any psychedelic effect and is amplified by monoamine oxidase inhibitors.[4]
Pharmacokinetics
No human pharmacokinetic data have been published for any route. In rats, bufotenin concentrates in the lungs and heart while reaching the brain at levels far lower than 5-MeO-DMT.[7] MAO-A is the primary clearance enzyme,[7] producing the same metabolite as serotonin.
Neuroscience[edit]
Where it acts
No human brain imaging studies of bufotenin exist. Experiments in rats confirm it is centrally active when it reaches the brain.[12][13] Under typical use conditions, its weak activity at the main psychedelic serotonin receptor means it probably does not produce the cortical disruption patterns that define DMT or psilocin.
Why it matters
The transmethylation hypothesis proposes that excess endogenous production of methylated tryptamines — including bufotenin — contributes to psychotic symptoms.[14] Elevated bufotenin levels in urine have been consistently found in schizophrenia and autism spectrum disorder,[15] though whether this is a cause or simply a marker of altered metabolism remains unresolved.
What is the actual receptor occupancy in the human brain after smoked administration? Does endogenous bufotenin serve a functional role in normal brain chemistry, or is it merely a metabolic byproduct?
Subjective Effects[edit]
The bufotenin experience is defined by physical sensation over mental content. Cardiovascular pressure, bodily weight, and flushing come first — vivid and difficult to ignore. Psychedelic content, when it appears, is modest and short-lived, easily eclipsed by what the body is doing.[6][4]
Compared to DMT — its closest relative by structure and duration — bufotenin is markedly more body-bound and less visually elaborate. Where DMT opens into vivid visual and transpersonal territory, bufotenin stays grounded in the physical. Most describe it as psychedelic only at higher doses.
Effect Grid
At common doses, the psychedelic character of bufotenin becomes apparent via the smoked route: visual drifting, color alteration, and geometric patterning emerge alongside emotional enhancement and thought connectivity. Euphoria is frequently reported. The experience has a compressed, intense quality — effects build rapidly (within seconds of inhalation) and peak within minutes.
Cardiovascular effects are pronounced — tachycardia, facial flushing, vasoconstriction (cold extremities, bodily pressures), and elevated blood pressure are the norm rather than the exception. Nausea and bodily heaviness are common. Motor control may be mildly impaired. The total experience typically spans 30-60 minutes when smoked.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Ganzfeld effect · Color enhancement · Vestibular distortion · Brightness alteration · Spatial disorientation · Visual breathing · Visual morphing · Touch enhancement · Music enhancement · After-images · Auditory distortion · Auditory enhancement · Depth perception distortion · Light sensitivity · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Sound sensitivity · Symmetrical texture repetition · Tracers · Visual diffraction · Visual haze / noise · Visual melting · Auditory misinterpretation · Peripheral misidentification · Synesthesia · Visual magnification · Visual acuity enhancement · Visual processing acceleration · Tinnitus · Internal hallucinations · Visual recursion · External hallucinations · Environmental orbism / cubism · Object transformations · Auditory hallucinations · Object activation · Perspective hallucinations · Visual flipping · Visual scenery slicing
Spatial disorientation · Visual breathing · Visual morphing · Touch enhancement · Music enhancement · After-images · Auditory distortion · Auditory enhancement · Depth perception distortion · Light sensitivity · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Sound sensitivity · Symmetrical texture repetition · Tracers · Visual diffraction · Visual haze / noise · Visual melting · Auditory misinterpretation · Peripheral misidentification · Synesthesia · Visual magnification · Visual acuity enhancement · Visual processing acceleration · Tinnitus · Internal hallucinations · Visual recursion · External hallucinations · Environmental orbism / cubism · Object transformations · Auditory hallucinations · Object activation · Perspective hallucinations · Visual flipping · Visual scenery slicing
Pupil dilation · Spontaneous body sensations · Bodily heaviness · Temperature dysregulation · Wakefulness · Body high · Dizziness · Heart rate perception changes · Tingling / electric sensations · Vibrations / buzzing · Appetite suppression · Body schema distortion · Breathing alteration · Excessive sweating · Muscle tension · Physical fatigue · Restlessness · Trembling · Involuntary body movements · Nystagmus (eye wobbles) · Salivation · Tactile euphoria · Vomiting · Watery eyes · Bodily dissociation · Tactile hallucination
Wakefulness · Body high · Dizziness · Heart rate perception changes · Tingling / electric sensations · Vibrations / buzzing · Appetite suppression · Body schema distortion · Breathing alteration · Excessive sweating · Muscle tension · Physical fatigue · Restlessness · Trembling · Involuntary body movements · Nystagmus (eye wobbles) · Salivation · Tactile euphoria · Vomiting · Watery eyes · Bodily dissociation · Tactile hallucination
Cognitive impairment · Confusion · Focus suppression · Immersion enhancement · Introspection enhancement · Novelty enhancement · Thought disorganization · Aesthetic enhancement · Analysis suppression · Cognitive dysphoria · Cognitive fatigue · Cognitive flexibility · Information processing suppression · Memory fragmentation · Multiple thought streams · Openness enhancement · Pattern recognition enhancement · Thought acceleration · Thought loops · Analysis enhancement · Creativity enhancement · Cognitive euphoria · Increased nature relatedness · Language suppression · Memory replays · Motivation suppression · Synchronicity · Thought deceleration · Information processing enhancement · Amnesia · Delusions · Delirium
Immersion enhancement · Introspection enhancement · Novelty enhancement · Thought disorganization · Aesthetic enhancement · Analysis suppression · Cognitive dysphoria · Cognitive fatigue · Cognitive flexibility · Information processing suppression · Memory fragmentation · Multiple thought streams · Openness enhancement · Pattern recognition enhancement · Thought acceleration · Thought loops · Analysis enhancement · Creativity enhancement · Cognitive euphoria · Increased nature relatedness · Language suppression · Memory replays · Motivation suppression · Synchronicity · Thought deceleration · Information processing enhancement · Delusions · Delirium
Catharsis · Dysphoria · Simultaneous emotions · Empathy enhancement · Anxiety suppression · Irritability
Anxiety suppression · Irritability
Sociability suppression · Social disconnection · Disinhibition · Social connection · Flow state · Boundary dissolution · Cognitive disconnection · Ego dissolution · Identity alteration · Telepathic feelings
Flow state · Boundary dissolution · Cognitive disconnection · Ego dissolution · Identity alteration · Telepathic feelings
Time cessation
Non-dual awareness · Transpersonal feelings · Transpersonal visions · Cessation · Near-death experience · Transpersonal memory access · Voidness
Near-death experience · Transpersonal memory access · Voidness
Recursive awareness
Timeline
Effects appear within seconds of inhalation — a rush of warmth, facial flushing, and a rapid shift in body awareness. Cardiovascular changes (increased heart rate, blood pressure rise) begin almost immediately.
Intensity escalates rapidly over 30 seconds to 2 minutes. Visual changes, bodily heaviness, and emotional amplification build concurrently with pronounced cardiovascular effects. The transition from first alerts to approaching peak is compressed compared to most psychedelics.
Maximum intensity spans roughly 5-20 minutes. Visual phenomena, thought connectivity, euphoria or anxiety, and cardiovascular effects are all at their strongest. The brevity and intensity create a compressed, immersive quality distinct from longer-acting tryptamines.
Effects diminish steadily over 10-45 minutes. Visuals fade, emotional intensity subsides, and cardiovascular effects gradually normalize. Residual bodily heaviness and mild disorientation may persist.
A mild residual state lasting 30 minutes to 2 hours — subtle mood changes, lingering body awareness, and gentle fatigue. Cardiovascular parameters typically return to baseline during this phase.
⚠ Do not drive or operate machinery until all residual effects have fully resolved, which may take several hours after smoking.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 2 hours
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- DMT · 5-MeO-DMT · psilo
Toxicity
No lethal dose has been established for bufotenin in any species. The toxic dose in humans is unknown, and no therapeutic index can be calculated.
Cardiovascular toxicity
Bufotenin constricts blood vessels and raises blood pressure,[1] while directly increasing heart rate and contraction force via cardiac serotonin receptors — confirmed in isolated human heart tissue.[4] These cardiac effects are amplified by monoamine oxidase inhibitors.[4]
Historical intravenous experiments in the 1950s consistently produced facial flushing, racing heart, and dangerous blood pressure spikes at doses intended to achieve psychedelic effects.[2][6]
Respiratory effects
Some historical reports describe breathing difficulty after systemic administration. The cause is unclear — possibly related to effects on lung blood vessels or secondary to anxiety.[6]
Stress response
Bufotenin raises stress hormones in rats through a mechanism distinct from typical serotonin pathways.[7]
Psychological risks
No controlled assessment of psychological risks exists. Anxiety is reported in user accounts and is consistent with serotonergic activation.
The transmethylation hypothesis suggests bufotenin overproduction may contribute to psychotic symptoms,[14][15] though whether exogenous administration reliably induces psychosis-like states is undetermined. Delusions and amnesia appear in community-sourced effect lists but lack clinical documentation.citation needed
Tolerance & Dependence
Tolerance reportedly builds almost immediately and resets within roughly 2 hours — consistent with other short-acting tryptamines, though not confirmed by bufotenin-specific research.inferred No physical dependence or withdrawal has been identified, consistent with the class-wide low abuse potential of serotonergic psychedelics. Cross-tolerance with psilocin, DMT, and LSD is expected but unconfirmed.inferred
Drug Interactions
Tramadol
Combining bufotenin with tramadol creates serious serotonin overload risk. Tramadol blocks serotonin reuptake and has caused fatal toxicity in combination with MAO inhibitors.[16][17] Bufotenin adds direct serotonin receptor activation and is cleared by the same enzyme.[7] The dual serotonergic load supports a dangerous interaction classification, though no bufotenin-specific case reports exist.
MAO inhibitors
MAO-A is bufotenin's primary clearance enzyme.[7] Blocking it dramatically slows elimination, raises blood levels, extends duration, and amplifies cardiac effects — confirmed in isolated human heart tissue.[4] Serotonin syndrome risk — a potentially life-threatening overheating and seizure response — is elevated with any MAO inhibitor combination.safety citation needed
Cannabis
No interaction data exist. Street bufotenin in the 1990s was typically smoked with marijuana,[3] confirming co-use occurs. No safety data on the combination have been published.
SSRIs and SNRIs
No bufotenin-specific data exist. Chronic SSRI use may blunt effects through receptor changes; acute co-use adds serotonergic load. This is a class-level inference.inferred
Contraindications
No published clinical contraindication guidelines specific to bufotenin exist. The following are inferred from pharmacological data.Heart conditions, high blood pressure, and irregular heart rhythm represent the most significant contraindication. Bufotenin directly raises heart rate and contraction force via cardiac serotonin receptors[4] and constricts blood vessels, creating substantial cardiovascular risk for anyone with pre-existing cardiac conditions.
Concurrent MAO inhibitor use is contraindicated because MAO-A is bufotenin's primary metabolic pathway.[7] Blocking it prevents clearance and dramatically raises serotonin syndrome risk.
Concurrent serotonergic medications (SSRIs, SNRIs, tramadol) increase total serotonergic burden, raising serotonin syndrome risk.
Personal or family history of psychotic disorders is a relative contraindication consistent with psychedelic class guidance, though bufotenin-specific evidence is absent.inferred
Harm Reduction[edit]
Forms & Identification
Bufotenin reaches users in forms that vary enormously in purity and composition. Anadenanthera seeds and toad secretions contain bufotenin alongside many other alkaloids — including 5-MeO-DMT and cardiac glycosides in toad venom — making actual bufotenin content unpredictable.
The dark resinous material historically sold as street bufotenin was identified only through forensic laboratory analysis.[3] Standard reagent kits cannot distinguish bufotenin from structurally similar tryptamines in natural preparations; analytical confirmation requires specialized methods beyond standard field kits.
Guidelines
- Test material with reagent kits where possible, recognizing that standard kits cannot distinguish bufotenin from other tryptamines in natural preparations.
- Start with the lowest amount when working with unfamiliar material — potency varies unpredictably across natural sources.
- Use only in a seated or reclined position. The rapid cardiovascular effects make standing or moving during onset risky.
- Have a sober sitter present who understands the short duration and the dominance of physical effects.
- Do not combine with monoamine oxidase inhibitors, tramadol, SSRIs, or other serotonergic substances.
- Avoid use entirely if any heart condition, high blood pressure, or irregular heart rhythm is present.
- Allow at least 2 hours between attempts — rapid tolerance development means immediate re-dosing increases cardiovascular load without proportional psychoactive effect.
Set & Setting
The intense cardiovascular and somatic effects make physical environment especially important. Flushing, pressure, and racing heart can easily tip into panic in unfamiliar or stimulating surroundings. A calm, seated environment with a trusted sitter present is essential, given the brief but intense onset when smoked.
Aftercare & integration. The bufotenin experience is brief but can be physically intense. After the acute effects resolve, rest and hydration support recovery from the cardiovascular stress. The somatic dominance of the experience — flushing, pressure, heart pounding — can leave residual anxiety about physical health; this typically resolves within hours.
If the experience produced distressing altered states or panic, journaling or talking through the experience with a trusted person can help process it. The brevity of bufotenin's effects means integration often focuses more on the body's response than on psychological content. Persistent anxiety, chest discomfort, or cardiovascular symptoms beyond 24 hours warrant medical evaluation.
Recovery & Support
Bufotenin does not produce physical dependence, and compulsive use patterns have not been documented. If use becomes a coping mechanism or part of a broader pattern of substance use, general psychedelic harm reduction resources and peer support communities can provide guidance. For persistent psychological distress following any psychedelic experience, professional support from a therapist familiar with psychedelic experiences is recommended.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, severe headache, difficulty breathing, loss of consciousness, or heart rate that remains dangerously elevated beyond the expected short duration distinguish a medical emergency from uncomfortable but self-limiting effects. Persistent blue or grey skin color around the lips or fingers indicates oxygen compromise.
- Call emergency services immediately if chest pain, difficulty breathing, loss of consciousness, or seizure occurs.
- Place the person in a comfortable seated position. If unconscious and breathing, use the recovery position.
- Do not attempt to make the person vomit.
- Monitor breathing and heart rate while waiting for help.
- Keep the environment calm and quiet — reduce stimulation.
Tell the dispatcher: the substance involved (bufotenin or toad-derived/seed-derived material), the route of administration, approximate time of use, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Bufotenin is explicitly named as a controlled substance in multiple jurisdictions — unlike newer tryptamines that fall under structural analog provisions, it has been specifically scheduled for decades.[5][8] It carries DEA Drug Code 7403 in the United States.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | DEA Drug Code 7403; classified as hallucinogen[5][8] |
| Illinois (US) | Schedule I | State-level scheduling effective February 2, 1996; listed under alternative names including mappine and N,N-dimethylserotonin[18] |
| United Kingdom | Class A, Schedule I (Misuse of Drugs Act 1971) | Most restrictive classification[5][8] |
| Australia | Schedule 9 (Prohibited Substance) | Under the Poisons Standard; 6 g triggers trial, 2 g indicates intent to supply[5] |
| New Zealand | Class A | Most restrictive category[8] |
| South Africa | Undesirable Dependence-Producing Substance | Listed under Drug and Drug Trafficking Act No. 140 of 1992[8] |
| Canada | Not explicitly scheduled | As of 2025[5] |
| Sweden | Suggested hazardous substance | Classification suggested May 2019[5] |
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]